/Investor DB

EQT Life Sciences — 2023 Investments

7 investments dated 2023 · listed companies and verified rows first · show all

Agomab Therapeuticsagomab.cominSeries C · Oct 2023 · $100M✓ verified

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.

BiotechHealthtechMedical DevicesAntwerp, BE

Tim Knotnerus(Chief Executive Officer)in

Co-investorsAdBio partnersAndera PartnersAsabys PartnersCanaan PartnersOmnes CapitalPontifax Venture Capital+2 more

MinervaXminervax.cominOct 2023 · $57M✓ verified

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSanofi VenturesSunstone Capital+2 more

Nouscomnouscom.comNov 2023✓ verified

Nouscom is a biotech company whose investors page lists its venture capital backers.

BiotechHealthtech

Riccardo Cortese(Co-Founder)Marina Udier(Chief Executive Officer and Board Director)Elisa Scarselli(Chief Scientific Officer and Co-Founder)Alfredo Nicosia(Co-founder)Antonella Folgori(Co-founder)Stefano Colloca(Co-founder)

Co-investors5AM VenturesAndera PartnersAngelini VenturesRevelation PartnersXGEN VentureBpifrance+7 more

VarmXvarmx.cominMay 2023✓ verified

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.

BiotechHealthtechMedical Devices

Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in

Co-investorsBioGeneration VenturesInkefSound BioventuresYsios CapitalEICUNIIQ+2 more

Lumeonlumeon.comin𝕏Aug 2023SEC filingmedium confidence

Lumeon provides an automated care orchestration platform that pulls data from health systems' care processes and existing systems and applies clinical intelligence to coordinate individualized patient care.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechBoston, US

Robbie Hughes(CEO and Founder)in

Board seatRudy Dekeyser· per SEC Form D · $12M raise · filed Aug 2023

Co-investorsEndeavour VisionOptum VenturesTechstarsAmadeus Capital Partners

Quralisquralis.comin𝕏Series B · Mar 2023 · $88M

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission Biocapital+8 more

Shinobi Therapeutics Inc.shinobitx.cominSeries A · Dec 2023 · $51M

Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAstellas Venture Management LLCF-Prime CapitalFast Track InitiativeJIC Venture Growth InvestmentsKyoto University Innovation Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.